Literature DB >> 22993403

Dual roles of PARP-1 promote cancer growth and progression.

Matthew J Schiewer1, Jonathan F Goodwin, Sumin Han, J Chad Brenner, Michael A Augello, Jeffry L Dean, Fengzhi Liu, Jamie L Planck, Preethi Ravindranathan, Arul M Chinnaiyan, Peter McCue, Leonard G Gomella, Ganesh V Raj, Adam P Dicker, Jonathan R Brody, John M Pascal, Margaret M Centenera, Lisa M Butler, Wayne D Tilley, Felix Y Feng, Karen E Knudsen.   

Abstract

UNLABELLED: PARP-1 is an abundant nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation. PARP-1 has well-described functions in DNA damage repair and also functions as a context-specific regulator of transcription factors. With multiple models, data show that PARP-1 elicits protumorigenic effects in androgen receptor (AR)-positive prostate cancer cells, in both the presence and absence of genotoxic insult. Mechanistically, PARP-1 is recruited to sites of AR function, therein promoting AR occupancy and AR function. It was further confirmed in genetically defined systems that PARP-1 supports AR transcriptional function, and that in models of advanced prostate cancer, PARP-1 enzymatic activity is enhanced, further linking PARP-1 to AR activity and disease progression. In vivo analyses show that PARP-1 activity is required for AR function in xenograft tumors, as well as tumor cell growth in vivo and generation and maintenance of castration resistance. Finally, in a novel explant system of primary human tumors, targeting PARP-1 potently suppresses tumor cell proliferation. Collectively, these studies identify novel functions of PARP-1 in promoting disease progression, and ultimately suggest that the dual functions of PARP-1 can be targeted in human prostate cancer to suppress tumor growth and progression to castration resistance. SIGNIFICANCE: These studies introduce a paradigm shift with regard to PARP-1 function in human malignancy, and suggest that the dual functions of PARP-1 in DNA damage repair and transcription factor regulation can be leveraged to suppress pathways critical for promalignant phenotypes in prostate cancer cells by modulation of the DNA damage response and hormone signaling pathways. The combined studies highlight the importance of dual PARP-1 function in malignancy and provide the basis for therapeutic targeting. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993403      PMCID: PMC3519969          DOI: 10.1158/2159-8290.CD-12-0120

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  63 in total

1.  Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome.

Authors:  Gangning Liang; Joy C Y Lin; Vivian Wei; Christine Yoo; Jonathan C Cheng; Carvell T Nguyen; Daniel J Weisenberger; Gerda Egger; Daiya Takai; Felicidad A Gonzales; Peter A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

2.  Poly(ADP-ribose) levels in carcinogen-treated cells.

Authors:  H Juarez-Salinas; J L Sims; M K Jacobson
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

3.  ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites.

Authors:  N Ogata; K Ueda; H Kagamiyama; O Hayaishi
Journal:  J Biol Chem       Date:  1980-08-25       Impact factor: 5.157

4.  ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA.

Authors:  R C Benjamin; D M Gill
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

5.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  (ADP-ribose)n participates in DNA excision repair.

Authors:  B W Durkacz; O Omidiji; D A Gray; S Shall
Journal:  Nature       Date:  1980-02-07       Impact factor: 49.962

Review 8.  PARP goes transcription.

Authors:  W Lee Kraus; John T Lis
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 9.  Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases.

Authors:  Alexei Tulin; Yurii Chinenov; Allan Spradling
Journal:  Curr Top Dev Biol       Date:  2003       Impact factor: 4.897

10.  Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci.

Authors:  Alexei Tulin; Allan Spradling
Journal:  Science       Date:  2003-01-24       Impact factor: 47.728

View more
  162 in total

1.  A hormone-DNA repair circuit governs the response to genotoxic insult.

Authors:  Jonathan F Goodwin; Matthew J Schiewer; Jeffry L Dean; Randy S Schrecengost; Renée de Leeuw; Sumin Han; Teng Ma; Robert B Den; Adam P Dicker; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

Review 2.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

Review 3.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

Review 4.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

5.  Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.

Authors:  Sumin Han; J Chad Brenner; Aaron Sabolch; Will Jackson; Corey Speers; Kari Wilder-Romans; Karen E Knudsen; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

6.  DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Authors:  Jonathan F Goodwin; Vishal Kothari; Justin M Drake; Shuang Zhao; Emanuela Dylgjeri; Jeffry L Dean; Matthew J Schiewer; Christopher McNair; Jennifer K Jones; Alvaro Aytes; Michael S Magee; Adam E Snook; Ziqi Zhu; Robert B Den; Ruth C Birbe; Leonard G Gomella; Nicholas A Graham; Ajay A Vashisht; James A Wohlschlegel; Thomas G Graeber; R Jeffrey Karnes; Mandeep Takhar; Elai Davicioni; Scott A Tomlins; Cory Abate-Shen; Nima Sharifi; Owen N Witte; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

7.  Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.

Authors:  Wenqi Wu; Hanliang Zhu; Yeping Liang; Zhenzhen Kong; Xiaolu Duan; Shujue Li; Zhijian Zhao; Dong Yang; Guohua Zeng
Journal:  Int Urol Nephrol       Date:  2014-01-17       Impact factor: 2.370

8.  Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.

Authors:  Ivyna Pau Ni Bong; Ching Ching Ng; Shaik Kamal Fakiruddin; Moon Nian Lim; Zubaidah Zakaria
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

Review 9.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

10.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.